/Companies

ACES Diagnostics

Paradise Valley, US · Founded 2024 · Delaware corporation

Find your way into ACES Diagnostics

417 people in our graph share verified history with the ACES Diagnostics team — schools, employers, funds. One of them is your warm intro.

Antonio Herceunlockedknows Todd Snowden · together at MiMARK (overlapped)
knows the team · via Robust Diagnostics, LLC
knows the team · via MiMARK
knows the team · via TGen
×8knows the team · via Motorola

Aces Diagnostics is developing LYMESEEK, an AI-driven blood test for detecting Lyme disease across all stages of the disease, aimed at physicians and clinical laboratories. The single blood-draw test runs on existing lab equipment and is being validated on clinical samples in the U.S. and E.U., with commercial launch anticipated in 2027.

Founders & leadership

ACES Diagnostics was founded in 2024 by Monica Embers, Holly Ahern, and Todd Snowden.

MEMonica Embers
Monica EmbersFounder & Chief Research Officer
HAHolly Ahern
Holly AhernFounder & Chief Scientific Officer
TSTodd Snowden
Todd SnowdenFounder & Chief Commercial OfficerTodd Snowden brings 35+ years of experience in medical device, diagnostics, and laboratory services, including roles in product management, sales leadership, and chief executive positions at startup and mid-size firms. His background spans regulatory strategy, commercialization, and international business development across the U.S., Europe, and Latin America.
TCTammy Crawford
Tammy CrawfordChief Executive OfficerTammy Crawford is CEO of ACES Diagnostics, where she leads development of an AI-driven blood test for Lyme disease diagnosis. She brings over 25 years of healthcare leadership experience, including roles at Baxter/American Hospital Supply, founding a national events company, and serving as Executive Director of Focus on Lyme, a nonprofit research organization.
LSLisa Stone
Lisa StoneChief Financial Officer
JK
Jim KirkChief Development Officer
PSPhillip Stafford
Phillip StaffordChief Data OfficerPhillip Stafford is Chief Data Officer at ACES Diagnostics, which develops AI-driven blood tests for disease detection including Lyme disease across all disease stages.

Reported raises · per SEC filings

Form D private placements

$4M disclosed across 2 rounds · 2024–2026

▶$400KraisedJun 2026 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Tammy CrawfordExecutive Officer, Director
Offering amount
$3M
Amount sold
$400K
Minimum investment
$25K
First sale
May 2026
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.6MraisedJun 2026 · 27 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Tammy CrawfordExecutive Officer, Director
Offering amount
$3.6M
Amount sold
$3.6M
Minimum investment
$25K
First sale
Jun 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Companies competing with ACES Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does ACES Diagnostics do?
Aces Diagnostics is developing LYMESEEK, an AI-driven blood test for detecting Lyme disease across all stages of the disease, aimed at physicians and clinical laboratories. The single blood-draw test runs on existing lab equipment and is being validated on clinical samples in the U.S. and E.U., with commercial launch anticipated in 2027.
Who founded ACES Diagnostics?
ACES Diagnostics was founded by Monica Embers, Holly Ahern, Todd Snowden in 2024.
How much funding has ACES Diagnostics raised?
ACES Diagnostics has disclosed $4M raised across 2 rounds.
Where is ACES Diagnostics headquartered?
ACES Diagnostics is headquartered in Paradise Valley, US.